ASMANEX provides physicians with a new treatment option to help manage children's asthma as back-to-school season approaches. () KENILWORTH, N.J., Aug. 19 /PRNewswire ...
April 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved mometasone furoate inhalation powder for the maintenance treatment of asthma as prophylactic therapy in patients aged 12 ...
In patients with mild asthma, mometasone furoate dry powder inhaler resulted in improved adherence and fewer exacerbations than beclomethasone dipropionate hydrofluoroalkane aerosol inhaler. Included ...
Asmanex Twisthaler has been launched by Schering-Plough as therapy in the control and management of mild, moderate or severe persistent asthma in Asmanex Twisthaler has been launched by ...
In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is less than 2% (low eosinophil level). The appropriate treatment for these patients is unknown. In this 42-week, ...
asthma inhaler overweight The FDA has approved updated labeling for Asmanex HFA (mometasone furoate; Merck) and Dulera (mometasone furoate, formoterol fumarate; Merck) to include use in pediatric ...
The FDA has approved Asmanex Twisthaler (mometasone furoate inhalation powder, from Schering-Plough) 110 mcg for the maintenance treatment of asthma as a preventive therapy in patients 4-11 years of ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA ® (mometasone furoate and formoterol fumarate dihydrate) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results